Nishadil
Signup Signin
Delhi | 25°C (windy)
Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape

Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape
India's Health Horizon: Ozempic's Green Light & A Tragic Mystery Illness Gripping Central India

India's Health Horizon: Ozempic's Green Light & A Tragic Mystery Illness Gripping Central India
LifeMD Unlocks Affordable Ozempic Access: A Game-Changer for Health Management

LifeMD Unlocks Affordable Ozempic Access: A Game-Changer for Health Management
The GLP-1 Gold Rush: Why Morgan Stanley Just Downgraded Novo Nordisk Amid Fierce Competition

The GLP-1 Gold Rush: Why Morgan Stanley Just Downgraded Novo Nordisk Amid Fierce Competition
Ozempic Arrives in India: A New Dawn for Type 2 Diabetes Management and Weight Loss

Ozempic Arrives in India: A New Dawn for Type 2 Diabetes Management and Weight Loss
Novo Nordisk's Groundbreaking Hemophilia A Treatment Nears FDA Review

Novo Nordisk's Groundbreaking Hemophilia A Treatment Nears FDA Review
The Race for the Next Weight Loss Breakthrough: Chinese Biotechs Challenge Global Giants

The Race for the Next Weight Loss Breakthrough: Chinese Biotechs Challenge Global Giants
Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s

Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s
Game Changer in Obesity Treatment: Novo Nordisk's Oral Wegovy Pill Achieves Remarkable 16.6% Weight Loss in Phase 3 Trial

Game Changer in Obesity Treatment: Novo Nordisk's Oral Wegovy Pill Achieves Remarkable 16.6% Weight Loss in Phase 3 Trial
The GLP-1 Revolution: Why the Market's Reaction to Novo Nordisk and Eli Lilly is Lagging

The GLP-1 Revolution: Why the Market's Reaction to Novo Nordisk and Eli Lilly is Lagging
FDA Steps In: Big Pharma's Weight-Loss Claims Under Scrutiny After Oprah Video

FDA Steps In: Big Pharma's Weight-Loss Claims Under Scrutiny After Oprah Video
FDA Slams Novo Nordisk's Oprah-Featured Weight Loss Ad as 'Misleading'

FDA Slams Novo Nordisk's Oprah-Featured Weight Loss Ad as 'Misleading'
Novo Nordisk Seeks Approval for Breakthrough Higher-Dose Wegovy, Promising Enhanced Weight Loss

Novo Nordisk Seeks Approval for Breakthrough Higher-Dose Wegovy, Promising Enhanced Weight Loss
The Final Verdict: Top Stock Picks Poised for Growth

The Final Verdict: Top Stock Picks Poised for Growth
The Startling Truth: Half of Weight Loss Drug Users Quit Within a Year

The Startling Truth: Half of Weight Loss Drug Users Quit Within a Year
The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance
The Next Frontier: Eli Lilly and Novo Nordisk Gear Up for a Revolution in Oral Obesity Treatment

The Next Frontier: Eli Lilly and Novo Nordisk Gear Up for a Revolution in Oral Obesity Treatment
Unlocking Healthcare's Future: How Breakthrough Treatments and Shifting Policies Are Reshaping the Market

Unlocking Healthcare's Future: How Breakthrough Treatments and Shifting Policies Are Reshaping the Market
Denmark's Golden Era: How Novo Nordisk and Ørsted Propelled a Nation, and What Lies Ahead

Denmark's Golden Era: How Novo Nordisk and Ørsted Propelled a Nation, and What Lies Ahead
The Ozempic Effect: How Weight-Loss Drugs Are Reshaping Economies and Creating Thousands of Jobs

The Ozempic Effect: How Weight-Loss Drugs Are Reshaping Economies and Creating Thousands of Jobs
The Weight of Success: Why Breakthrough Obesity Drugs Are a Budget Breaker

The Weight of Success: Why Breakthrough Obesity Drugs Are a Budget Breaker
Ozempic's Boom Sparks Paradox: Novo Nordisk to Shed Up to 9,000 Jobs Amid Record Profits

Ozempic's Boom Sparks Paradox: Novo Nordisk to Shed Up to 9,000 Jobs Amid Record Profits
Novo Nordisk's Strategic Overhaul: 9,000 Job Cuts to Propel Future Dominance

Novo Nordisk's Strategic Overhaul: 9,000 Job Cuts to Propel Future Dominance
The Unseen Risks: Ozempic, Weight Loss Drugs, and the Critical Questions for Pregnancy

The Unseen Risks: Ozempic, Weight Loss Drugs, and the Critical Questions for Pregnancy
The Cost-Benefit Revolution: GLP-1 Drugs Deemed Value-Packed, But Price Tags Loom Large

The Cost-Benefit Revolution: GLP-1 Drugs Deemed Value-Packed, But Price Tags Loom Large
A New Era in Health: WHO Adds Mounjaro and Ozempic to Essential Medicines List

A New Era in Health: WHO Adds Mounjaro and Ozempic to Essential Medicines List
Wegovy's Astonishing Revelation: A Game Changer for Heart Health, Beyond Weight Loss

Wegovy's Astonishing Revelation: A Game Changer for Heart Health, Beyond Weight Loss
Wegovy Triumphs: Novo Nordisk's Obesity Drug Significantly Cuts Heart Attack and Stroke Risk, Setting a New Benchmark in Cardiovascular Protection

Wegovy Triumphs: Novo Nordisk's Obesity Drug Significantly Cuts Heart Attack and Stroke Risk, Setting a New Benchmark in Cardiovascular Protection
Wegovy's Game-Changing Heart-Saving Revelation: Redefining Obesity Treatment

Wegovy's Game-Changing Heart-Saving Revelation: Redefining Obesity Treatment
Pharma Giant Novo Nordisk Unveils Staggering $2 Billion Investment in North Carolina Amidst Soaring Demand and Bullish Market Outlook

Pharma Giant Novo Nordisk Unveils Staggering $2 Billion Investment in North Carolina Amidst Soaring Demand and Bullish Market Outlook
A Breakthrough in Affordability: Ozempic Now Half Price for Cash Customers Through GoodRx Partnership

A Breakthrough in Affordability: Ozempic Now Half Price for Cash Customers Through GoodRx Partnership
The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?
Healthcare Titans: UnitedHealth vs. Novo Nordisk – Which Giant Dominates Your Portfolio?

Healthcare Titans: UnitedHealth vs. Novo Nordisk – Which Giant Dominates Your Portfolio?
Load more..